151 related articles for article (PubMed ID: 23361927)
1. Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab).
Ribera JM; García O; Grande C; Esteve J; Oriol A; Bergua J; González-Campos J; Vall-Llovera F; Tormo M; Hernández-Rivas JM; García D; Brunet S; Alonso N; Barba P; Miralles P; Llorente A; Montesinos P; Moreno MJ; Hernández-Rivas JÁ; Bernal T
Cancer; 2013 May; 119(9):1660-8. PubMed ID: 23361927
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients.
Oriol A; Ribera JM; Bergua J; Giménez Mesa E; Grande C; Esteve J; Brunet S; Moreno MJ; Escoda L; Hernandez-Rivas JM; Hoelzer D
Cancer; 2008 Jul; 113(1):117-25. PubMed ID: 18457327
[TBL] [Abstract][Full Text] [Related]
3. Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study.
Oriol A; Ribera JM; Esteve J; Sanz MA; Brunet S; Garcia-Boyero R; Fernández-Abellán P; Martí JM; Abella E; Sánchez-Delgado M; Peñarrubia MJ; Besalduch J; Moreno MJ; Borrego D; Feliu E; Ortega JJ;
Haematologica; 2003 Apr; 88(4):445-53. PubMed ID: 12681972
[TBL] [Abstract][Full Text] [Related]
4. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
[TBL] [Abstract][Full Text] [Related]
5. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.
Evens AM; Carson KR; Kolesar J; Nabhan C; Helenowski I; Islam N; Jovanovic B; Barr PM; Caimi PF; Gregory SA; Gordon LI
Ann Oncol; 2013 Dec; 24(12):3076-81. PubMed ID: 24146219
[TBL] [Abstract][Full Text] [Related]
6. Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients.
Xicoy B; Ribera JM; Müller M; García O; Hoffmann C; Oriol A; Hentrich M; Grande C; Wasmuth JC; Esteve J; van Lunzen J; Del Potro E; Knechten H; Brunet S; Mayr C; Escoda L; Schommers P; Alonso N; Vall-Llovera F; Pérez M; Morgades M; González J; Fernández A; Thoden J; Gökbuget N; Hoelzer D; Fätkenheuer G; Wyen C;
Leuk Lymphoma; 2014 Oct; 55(10):2341-8. PubMed ID: 24397614
[TBL] [Abstract][Full Text] [Related]
7. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
Sun XF; Zhen ZJ; Liu DG; Xia Y; Xiang XJ; Chen XQ; Ling JY; Zheng L; Luo WB; Lin H; He YJ; Guan ZZ
Ai Zheng; 2007 Dec; 26(12):1339-43. PubMed ID: 18076797
[TBL] [Abstract][Full Text] [Related]
9. [The specific features of renal lesion in Burkitt's lymphoma].
Lukina AE; Bariakh EA; Kravchenko SK; Biriukova LS; Gemdzhian ÉG; Magomedova AU; Kremenetskaia AM; Vorob'ev AI
Ter Arkh; 2012; 84(7):31-4. PubMed ID: 23038969
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study of 40 children with Burkitt's and Burkitt-like lymphoma].
Zhang YH; Duan YL; Yang J; Jin L; Zhou CJ; Gao ZF
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):209-14. PubMed ID: 19099711
[TBL] [Abstract][Full Text] [Related]
11. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma.
Pohlen M; Gerth HU; Liersch R; Koschmieder S; Mesters RM; Kessler T; Appelmann I; Müller-Tidow C; Berdel WE
Am J Hematol; 2011 Dec; 86(12):E61-4. PubMed ID: 21898532
[TBL] [Abstract][Full Text] [Related]
13. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia.
Todeschini G; Bonifacio M; Tecchio C; Balter R; Carli G; Stefani PM; Adami F; Zamò A; Dei Tos AP; Marino F; Gherlinzoni F; Marradi P; Semenzato G; Pizzolo G
Am J Hematol; 2012 Jan; 87(1):22-5. PubMed ID: 22086870
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of the efficacy of CCCG-97 and BFM-90 protocols in the treatment for children with mature B-cell non-Hodgkin's lymphoma].
Meng JH; Gao YJ; Lu FJ; Zhai XW; Wang HS; Li J
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):222-7. PubMed ID: 22780979
[TBL] [Abstract][Full Text] [Related]
15. [Therapy for Burkitt's lymphoma according to the BL-M-04 protocol: 12-year experience].
Baryakh EA; Tyurina NG; Vorobyev VI; Gemdzhyan EG; Mangasarova YK; Klyasova GA; Kovrigina AM; Obukhova TN; Zvonkov EE; Vernyuk MA; Chervontseva AM; Polyakov YY; Misyurina АЕ; Valiev TT; Zherebtsova VA; Magomedova AU; Galstyan GM; Yatskov KV; Nesterova ES; Vorobyev AI; Kravchenko SK
Ter Arkh; 2015; 87(7):4-14. PubMed ID: 26390720
[TBL] [Abstract][Full Text] [Related]
16. Treatment of older patients with mantle-cell lymphoma.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
Barnes JA; Lacasce AS; Feng Y; Toomey CE; Neuberg D; Michaelson JS; Hochberg EP; Abramson JS
Ann Oncol; 2011 Aug; 22(8):1859-64. PubMed ID: 21339382
[TBL] [Abstract][Full Text] [Related]
18. Comparison of CHOP treatment with specific short-intensive chemotherapy in AIDS-related Burkitt's lymphoma or leukemia.
Xicoy B; Ribera JM; Miralles P; La Cruz J; Oriol A; Valencia E; Morgades M; Mahillo B; de la Torre J; Téllez MJ; Brunet S; Esteve J; Hoelzer D; ; ;
Med Clin (Barc); 2011 Mar; 136(8):323-8. PubMed ID: 21251683
[TBL] [Abstract][Full Text] [Related]
19. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
[TBL] [Abstract][Full Text] [Related]
20. Small non-cleaved-cell lymphoma (undifferentiated lymphoma, Burkitt's type) in American adults: results with treatment designed for acute lymphoblastic leukemia.
Straus DJ; Wong GY; Liu J; Oppenberg J; Filippa DA; Gold JW; Offit K; Clarkson BD
Am J Med; 1991 Mar; 90(3):328-37. PubMed ID: 2003515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
